Watson Laboratories files raloxifene hydrochloride tablet ANDA

[News]

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.

More... (http://www.news-medical.net/news/20100506/Watson-Laboratories-files-raloxifene-hydrochloride-tablet-ANDA.aspx)